US Liver Diseases Therapeutics Market Analysis

US Liver Disease Therapeutics Market Executive Summary

The US market for therapies for liver disease is anticipated to increase from $9.7 billion in 2022 to $13 billion in 2030, with a CAGR of 3.7% from 2022 to 2030.

The market for treatments for liver illnesses in the US is expanding quickly due to the rising incidence of liver diseases such as hepatitis, liver cancer, and non-alcoholic fatty liver disease (NAFLD). For the therapy of liver illness, a variety of medications and therapeutic modalities are available on the market, including immunosuppressants, antiviral medications, and liver transplant treatments.

One of the main reasons propelling the market's expansion is the rising prevalence of liver illnesses, as well as the rising need for liver transplants and the creation of novel and cutting-edge medications.

Gilead Sciences, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb, and Novartis AG are a few of the major companies active in the US liver disease treatment industry. In the next years, it is anticipated that these businesses, which are making significant investments in research & development to create novel therapies for liver disease, will continue to drive market expansion.

Market Dynamics

Growth Drivers

The major population with liver diseases, the rise in alcohol consumption, and poor eating habits are the key drivers that are likely to propel market growth for therapeutics for liver disease. A research study published in the Clinical Liver Disease journal in June 2021 claims that chronic liver disease (CLD), which affects approximately 1.5 billion people globally, is one of the main causes of illness and death in the world. The American Association for the Study of Liver Diseases published a study in June 2021 that found non-alcoholic fatty liver disease (NAFLD) to be the most common cause of prevalent disease, followed by hepatitis B (29%), hepatitis C (9%), and alcoholic liver disease (ALD) (2%). By 2040, it is expected that 55.7% of Americans will have non-alcoholic fatty liver disease (NAFLD). Consequently, rising liver diseases have influenced the market's overall growth.

Competitive Landscape

Key Players

There are several key players in the US liver disease therapeutics market, including:

• Gilead Sciences, Inc.
• AbbVie Inc.
• Intercept Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Pfizer Inc.
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company

These businesses are engaged in the research, development, production, and marketing of a variety of medications and therapies for the treatment of liver diseases, such as medications for the management of hepatitis B and C, nonalcoholic fatty liver disease (NAFLD), and other liver-related conditions. To advance our understanding of liver disease and create new treatments, they also make significant investments in research and development and collaborate with academic institutions and other industry partners.

Smaller biotech firms and academic institutions that are creating and evaluating novel liver disease therapies could be some of the local key players in the market. These regional players might be more aware of the particular requirements and difficulties faced by patients in their region, and they might take a more targeted or specialized approach to the development and marketing of liver disease treatments. Research organizations like the Mayo Clinic, hospitals with specialized liver disease centers, and smaller biotech companies creating cutting-edge new liver disease treatments are a few examples of regionally significant players in the US liver disease therapeutics market.

Healthcare Policies and Regulatory Landscape

The research, approval, and marketing of medications and treatments for the treatment of a liver illness are impacted by a number of healthcare regulations and laws that a to the US market for medicines for liver disease.

The US Food and Drug Administration (FDA), which is in charge of overseeing the clearance process for new pharmaceuticals and treatments, controls the regulatory environment for liver disease therapeutics in the main. Before approving a new medication or treatment for sale on the US market, the FDA conducts comprehensive clinical testing and data analysis. The FDA also mandates continued surveillance and reporting of unfavorable outcomes and other safety issues pertaining to medications for liver disease.

The US healthcare system is governed by a number of policies and initiatives in addition to legislative requirements with the goal of enhancing access to treatment and controlling costs. For instance, the Affordable Care Act (ACA) has measures intended at enhancing access to health insurance coverage and lowering healthcare expenses, which may have an effect on the accessibility and affordability of therapies for people with liver disease.

The development and availability of novel medicines, as well as the cost and patient accessibility of current treatments, may all be impacted by the regulatory environment and healthcare policy in the US market for liver disease therapeutics. Hence, to bring innovative medicines to market and guarantee that patients have access to the treatments they need, pharmaceutical firms engaged in this sector must negotiate a complicated and quickly changing regulatory and policy environment.